Travis Steed
Stock Analyst at Barclays
(2.74)
# 2,103
Out of 4,970 analysts
86
Total ratings
44.93%
Success rate
6.49%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $191.26 | +36.46% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $279.72 | +14.40% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $132.81 | +12.94% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $72.38 | +17.44% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $80.96 | +11.17% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $12.33 | +159.53% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $23.58 | +90.84% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $13.35 | +237.08% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $394.34 | -20.12% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $346.47 | -14.86% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $15.40 | +3.90% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $12.39 | +166.34% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $104.76 | +52.73% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $454.52 | -30.70% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.74 | +359.77% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $14.49 | +72.53% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.41 | +489.87% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $80.76 | +54.78% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $92.85 | +56.17% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $107.29 | -52.47% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $54.69 | +219.99% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $15.64 | +245.27% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $53.82 | -59.12% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $191.26
Upside: +36.46%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $279.72
Upside: +14.40%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $132.81
Upside: +12.94%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $72.38
Upside: +17.44%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $80.96
Upside: +11.17%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $12.33
Upside: +159.53%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $23.58
Upside: +90.84%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $13.35
Upside: +237.08%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $394.34
Upside: -20.12%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $346.47
Upside: -14.86%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $15.40
Upside: +3.90%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $12.39
Upside: +166.34%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $104.76
Upside: +52.73%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $454.52
Upside: -30.70%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.74
Upside: +359.77%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $14.49
Upside: +72.53%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.41
Upside: +489.87%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $80.76
Upside: +54.78%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $92.85
Upside: +56.17%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $107.29
Upside: -52.47%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $54.69
Upside: +219.99%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $15.64
Upside: +245.27%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $53.82
Upside: -59.12%